Poster Abstracts • OFID 2019:6 (Suppl 2) • S331 Background. Cefiderocol is a siderophore cephalosporin discovered by Shionogi & Co., Ltd., which exhibits potent efficacy against Gram-negative carbapenem-resistant bacteria. Pediatric clinical studies are planned. Cefiderocol is mainly renally eliminated. A 2-g infusion of cefiderocol over 3 hours, every 8 hours (q8h) is the recommended dose regimen in adults. In this study, dose regimens for pediatric subjects (birth to <18 years old) are proposed based on predictions of pharmacokinetics (PK) in pediatrics using data from adults to provide adequate exposure.
Session: 69. What's New in Clinical Practice? Thursday, October 3, 2019: 12:15 PM Background. Outpatient parenteral antibiotic therapy (OPAT) is an effective way to provide long-term antibiotic therapy and simultaneously decrease hospital length of stay, minimize costs and improve patient satisfaction. However, OPAT is not always an efficient process and there are systemic challenges to providing adequate care and ensuring close follow-up. The aims of this project are to define the OPAT process at three New Orleans hospitals staffed by the Tulane Infectious Diseases Section and to determine process outcomes among patients receiving OPAT in different settings.
Methods. We utilized the knowledge of medicine residents, infectious diseases (ID) fellows and social workers to create a process map defining the current OPAT system [ Figure 1 ]. We performed a retrospective chart review identifying patients who were discharged with OPAT from August 1, 2018 to November 30, 2018. The patients received OPAT in a variety of settings: long-term acute care facilities (LTACs), infusion centers, home, hemodialysis centers and prison. We measured the following process outcomes: if the patient arrived to an ID appointment, if safety laboratory results were available for review and if the patient completed the pre-specified antibiotic course. These outcomes were compared amongst the OPAT delivery settings.
Results. Our retrospective analysis identified 62 patients discharged with OPAT, although 2 patients were excluded due to lack of availability of records. Only 42% completed the pre-specified antibiotic course, 54% arrived to ID follow-up, and 38% had laboratory results available. We compared the completion of antibiotic course amongst the different OPAT settings (Figure 2 ). The highest rates of incompletion were amongst LTAC patients (n = 19, 73%) and prisoners (n = 3, 75%). Given that the highest number of patients who did not complete antibiotics were discharged to LTACs, we plan further investigation and intervention to target this population.
Conclusion. Patient outcomes among OPAT patients discharged from three New Orleans hospitals are poor, as evidenced by 58% failing to complete their pre-specified antibiotic course. The highest number of patients who failed were LTAC patients. We propose a further investigation into this population in order to improve the efficacy of the OPAT system.
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No reported disclosures. Thursday, October 3, 2019: 12:15 PM Background. Increasing international travel places larger populations at risk for infections outside of their usual exposure. Deployed military personnel have unique risks for such infections. Our cohort's rates of travelers' diarrhea and influenza-like illness have been defined, but the rate of travelers with symptoms apart from a clinical syndrome has not. We present a survey of intra-travel symptoms of all travelers and confirmed diagnoses of ill-returned travelers in a cohort of military and civilian travelers.
TravMil Surveillance of Travel-Related Illness in a Prospective Cohort of US
Methods. TravMil is a prospective, multicenter observational study enrolling US military beneficiaries traveling outside the continental United States from 2010-2018; beneficiaries could also enroll after travel if they presented for a possible travel-related illness. Demographic information, intra-travel symptoms, and confirmed diagnoses were recorded.
